The tightened guidance and margin improvement signal operational momentum, but the massive Q2 EPS miss and activist/poison pill dynamics create uncertainty. Watch the Q3 2026 earnings call in November for actual revenue, EBITDA, and free cash flow conversion. The rights offering closure reduces near-term bankruptcy risk but dilutes existing holders.
Price Chart
Executive Summary
KLX Energy Services tightened Q3 2026 revenue guidance to $180M-$185M (midpoint ~9% sequential growth) and guided to 13%-14% Adjusted EBITDA margin, a ~200bp sequential improvement. The $125M rights offering closed successfully, delevering the balance sheet. However, the most recent reported quarter (Q2 2026) showed a steep EPS miss of -$0.72 vs consensus -$0.12, and the stock has been volatile amid activist activity and a poison pill adoption.
Key Financial Metrics
Key Facts
- Q3 2026 revenue guidance tightened to $180M-$185M, implying ~9% sequential growth from Q2 2026
- Q3 2026 Adjusted EBITDA margin guided to 13%-14%, ~200bp sequential improvement
- Adjusted EBITDA expected to improve ~30% at the midpoint of guidance
- $125M equity rights offering closed successfully; company describes it as a 'transformational step' to delever
- Wolf Pack acquisition contributing a full quarter; $2.5M annual synergy target on track
- Most recent reported quarter (Q2 2026) EPS of -$0.72 missed consensus of -$0.12 by 500%
- Poison pill adopted on September 23, 2026 with 10% trigger, expiring September 2027
- Steel Partners filed SC 13D on September 3, 2026, indicating activist presence
Financial Impact
Q3 revenue midpoint ~$182.5M vs prior guidance range; sequential revenue growth ~9%; Adjusted EBITDA margin 13%-14% vs Q2 2026 margin; $125M rights offering proceeds used to reduce debt
Risk Factors
- Oil and gas commodity price volatility could reverse sequential revenue growth
- Integration of Wolf Pack acquisition may not achieve $2.5M synergy target
- Activist Steel Partners may push for further strategic changes, creating board-level conflict
- Poison pill limits stock accumulation and could deter potential acquirers
- High leverage remains despite rights offering; debt service costs could pressure margins
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302890594 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 3 | $1.30 $1.27 | ▼ −2.31% | ▼ −0.81% | $1.15 (−11.50%) |
Oct 9, 2026 17d ago | 3 | $1.32 $1.32 | · 0.00% | ▲ +1.97% | $1.15 (−12.84%) |
Oct 6, 2026 20d ago | SC 13D | $1.30 $1.31 | ▲ +0.77% | ▲ +1.75% | $1.15 (−11.50%) |
Oct 6, 2026 20d ago | SC 13D | $1.30 $1.31 | ▲ +0.77% | ▲ +1.75% | $1.15 (−11.50%) |
Sep 30, 2026 26d ago | 8-K | $1.41 $1.26 | ▼ −10.64% | ▼ −11.94% | $1.15 (−18.40%) |
Sep 25, 2026 4w ago | 8-K | $1.52 $1.37 | ▼ −9.87% | ▼ −11.07% | $1.15 (−24.31%) |
Sep 25, 2026 4w ago | Press Release | $1.52 $1.37 | ▼ −9.87% | ▼ −11.07% | $1.15 (−24.31%) |
Sep 24, 2026 4w ago | 25-NSE | $1.47 $1.41 | ▲ +4.08% | ▲ +3.67% | $1.15 (+21.73%) |
Sep 23, 2026 4w ago | 8-K | $1.47 $1.41 | ▲ +4.08% | ▲ +3.67% | $1.15 (+21.73%) |
Sep 18, 2026 5w ago | 8-K | $1.52 $1.61 | ▲ +5.92% | ▲ +4.65% | $1.15 (−24.31%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers